Skip to main content

Dr. Eisner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Eisner's full profile

Already have an account?

  • Office

    38135 Market Square
    Zephyrhills, FL 33542
    Phone+1 813-780-7534
    Fax+1 813-715-1810

Education & Training

  • George Washington University
    George Washington UniversityFellowship, Gastroenterology, 1988 - 1990
  • Johns Hopkins University/Bayview Medical Center
    Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 1985 - 1988
  • George Washington University School of Medicine and Health Sciences
    George Washington University School of Medicine and Health SciencesClass of 1985

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 1990 - 2026
  • MD State Medical License
    MD State Medical License 1986 - 1990
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Intergy EHR, Greenway Health, LLC, 2012

Press Mentions

  • Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
    Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis DeltaDecember 12th, 2024
  • Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
    Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines AgencyNovember 18th, 2024